These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38691665)

  • 21. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
    Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
    JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers.
    Wang J; Chen X; Yuan B; Wang W; Xu C; Zhao W; Zhao P; Wang Y; Zhao X; Wang Y
    Clin Ther; 2018 Oct; 40(10):1683-1691. PubMed ID: 30241688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells.
    Li Q; Feng Y; Xue Y; Zhan X; Fu Y; Gui G; Zhou W; Richard JP; Taga A; Li P; Mao X; Maragakis NJ; Ying M
    Mol Neurodegener; 2022 Jan; 17(1):8. PubMed ID: 35012575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults.
    Shimizu H; Nishimura Y; Shiide Y; Matsuda H; Akimoto M; Matsuda M; Nakamaru Y; Kato Y; Kondo K
    Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1174-1187. PubMed ID: 33704925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy.
    Fortuna A; Gizzi M; Bello L; Martinelli I; Bertolin C; Pegoraro E; Corbetta M; Sorarù G;
    J Neurol Sci; 2019 Sep; 404():47-51. PubMed ID: 31325668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis.
    Brooks BR; Pioro EP; Sakata T; Takahashi F; Hagan M; Apple S
    Muscle Nerve; 2023 Oct; 68(4):397-403. PubMed ID: 37525592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Drugs for Amyotrophic Lateral Sclerosis].
    Ogino M
    Brain Nerve; 2023 May; 75(5):503-506. PubMed ID: 37194520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study.
    Park JM; Park D; Kim HJ; Park JS
    BMC Neurol; 2022 Jul; 22(1):260. PubMed ID: 35836136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis.
    Ohta Y; Nomura E; Shang J; Feng T; Huang Y; Liu X; Shi X; Nakano Y; Hishikawa N; Sato K; Takemoto M; Yamashita T; Abe K
    J Neurosci Res; 2019 May; 97(5):607-619. PubMed ID: 30565312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population.
    Tomar S; Gupta S; Singal A; Soni R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early post-marketing experience with edaravone in an unselected group of patients with ALS.
    Abraham A; Nefussy B; Fainmesser Y; Ebrahimi Y; Karni A; Drory VE
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 May; 20(3-4):260-263. PubMed ID: 30784320
    [No Abstract]   [Full Text] [Related]  

  • 33. A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial.
    Srinivasan V; Homer V; Barton D; Clutterbuck-James A; Jenkins S; Potter C; Brock K; Logan A; Smith D; Bruce L; Nagy Z; Bach SP
    PLoS One; 2024; 19(7):e0291285. PubMed ID: 38990927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).
    Shefner J; Heiman-Patterson T; Pioro EP; Wiedau-Pazos M; Liu S; Zhang J; Agnese W; Apple S
    Muscle Nerve; 2020 Feb; 61(2):218-221. PubMed ID: 31621933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience.
    Ismail II; Massoud F; Kamel WA; Al-Hashel JY
    Acta Neurol Belg; 2021 Dec; 121(6):1591-1597. PubMed ID: 32651875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of the US Safety Data for Edaravone (Radicava
    Genge A; Brooks BR; Oskarsson B; Kalin A; Ji M; Apple S; Bower L
    Drugs R D; 2022 Sep; 22(3):205-211. PubMed ID: 35723868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In brief: Edaravone oral suspension (Radicava ORS) for ALS.
    Med Lett Drugs Ther; 2022 Sep; 64(1658):e1. PubMed ID: 36098666
    [No Abstract]   [Full Text] [Related]  

  • 38. Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
    Ikeda K; Iwasaki Y
    PLoS One; 2015; 10(10):e0140316. PubMed ID: 26469273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Edaravone: A New Treatment for ALS].
    Yamashita T; Abe K
    Brain Nerve; 2019 Nov; 71(11):1245-1251. PubMed ID: 31722310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch.
    Jackson C; Heiman-Patterson T; Kittrell P; Baranovsky T; McAnanama G; Bower L; Agnese W; Martin M
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 Nov; 20(7-8):605-610. PubMed ID: 31364409
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.